No Disease Activity After 4 Years for Patients on Kesimpta & Comparing Cases of MS

Jul 08, 2022, 12:00 AM

Episode image
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how ALITHIOS trial participants who started on Kesimpta were about four times more likely to have no MS symptoms than those starting on Aubagio.
He also reads “Comparing Cases of Multiple Sclerosis Leads to a Logical Fallacy” by Benjamin Hofmeister, from his column “Chairborne.”
===================================
Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/
=====================================
To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/